When: Confirmed breakout above $410 with MACD cross + close above 50 SMA on volume

Then: Upgrade rating to Buy

When: Pullback to $385-395 with RSI>45 and MACD contracting

Then: Upgrade rating to Buy

When: 200 SMA weekly close at $357 AND Q3 op margin reverts below 32% AND any adverse MariTide pre-readout (compound three-condition trigger)

Then: Downgrade rating to Underweight

HOLD current position; do not chase at $406; wait for entry triggers

• Consensus PT of $388 is post-catalyst and reflects updated models (Simply Wall St. moved from $371.93 to $388.03), not a stale anchor — price at $406 is already 5% above refreshed fair value
• Forward P/E of 16.62x requires 52% EPS growth to justify, representing priced-in optimism rather than cheapness; trailing P/E is 25.25x with PEG of 2.48
• Q2 2025 had a one-time non-operating gain of $2.08 billion inflating net income, making YoY comparisons partially optical
• MACD hasn't crossed, RSI is at 52, and volume on breakout day was supportive but not explosive — suggesting the market has accepted the news rather than underreacting
• Bollinger middle band at $409 represents profit-taking resistance from Sep 18 reversal and Sep 23 breakout buyers
• Risk-reward math: waiting for MACD confirmation costs 1.5% in upside scenario vs. 5.2% loss if buying now and price pulls to $385
• If MariTide disappoints, multiple could compress from 16.6x to 18x trailing, representing approximately 28% downside
• Beta of 0.43 means the stock underperforms in sustained risk-on rallies; dividend yield of 2.46% with 1.9x FCF coverage is a reason to hold, not chase
• Entry triggers: breakout above $410 with MACD confirmation OR pullback to $385-$395 zone with RSI support above 45
• Current position is 7.6% above the Sep lows at $377; the 200 SMA sits at $357, representing 14% downside from current levels if broken

→ vs aggressive: The $388 consensus PT is not stale — Simply Wall St.'s model was updated to $388.03 from $371.93 AFTER the dazodalibep readout, meaning price at $406 has already exceeded the refreshed fair value

→ vs aggressive: The 15% drawdown followed by recovery is not market underreaction — it is position reduction ahead of binary risk followed by efficient pricing of the positive outcome

→ vs aggressive: MACD non-cross and Bollinger middle band at $409 are not 'permission gates' but risk gates — waiting for confirmation costs 1.5% vs. not waiting costing 5.2% on a pullback to $385

→ vs aggressive: The forward P/E of 16.62x requiring 52% EPS growth is not a sign of cheapness — it is priced-in optimism that requires execution perfection on MariTide and margin expansion

→ vs aggressive: The scaled entry proposal with stop at $375 reveals a gap risk problem — if price breaks $375, the next reference is the 200 SMA at $357, a 14% move from current, suggesting non-linear downside risk not fully accounted for

→ vs aggressive: Using NVO's 7% pipeline drop to argue for AMGN success is cherry-picking — the same binary volatility dynamic that crushed NVO applies to AMGN ahead of MariTide

HOLD for existing holders; modest tactical entry for new capital with half-position at $406 stop $385, add second half on MACD cross or pullback to $385-$395 with RSI above 45. Target $440-$447 stretch $465. Max position size 3%.

• Consensus PT at $388 is not stale — Simply Wall St. updated post-news to $388.03, reflecting broader analytical community hasn't rushed to upgrade; marginal model says $388, not wrong, just slow-moving
• Market reduced exposure ahead of binary risk then re-added on confirmation — stock recovered to $406 not $440, suggesting marginal buyer not chasing; MACD hasn't crossed, RSI at 52, volume supportive but not explosive
• Q2 2025 comparison is optical — had $2.08B non-operating gain inflating net income; underlying earnings strong but 83% FCF growth and 600bps margin expansion not as clean as they appear
• Stop at $375 means 7.6% risk but $357 200 SMA reference means 14% total gap risk on adverse news given $43B net debt and $39B intangibles
• MariTide binary event is more distant than conservative framing — Q3 late October won't be commercial launch metrics event; MariTide commercial validation is 2027 story
• Stable macro is neutral to slightly supportive — means optionality reasonably priced, supports measured action not maximum patience
• Beta 0.43 cuts both ways — shallower drawdowns and steadier recoveries means stop-loss framework more reliable, supporting measured entry

→ vs aggressive: Consensus PT at $388 is not stale — broader analytical community has had days to digest dazodalibep data and marginal model is still at $388; slow-moving is not the same as wrong

→ vs aggressive: Stock recovered to $406 not $440 — MACD hasn't crossed, RSI at 52, volume supportive but not explosive; smart money reduced exposure ahead of binary risk then re-added, not underreacting

→ vs aggressive: Q2 2025 comparison optical due to $2.08B non-operating gain; 83% FCF growth and 600bps margin expansion not as clean as presented

→ vs aggressive: Entry at $406 with stop at $375 means 14% gap risk to 200 SMA at $357 on adverse news given $43B net debt and $39B intangibles; tail risk not fully internalized

→ vs conservative: Catalyst is not fully priced in — first-in-class CD40L antagonist hitting primary endpoint in indication with zero approved disease-modifying therapies represents multi-billion-dollar TAM with no competition

→ vs conservative: Cost of waiting vs acting math assumes equal probability but aggressive analyst's momentum signals elevate continuation probability; expected value calculation not as clean as framed

→ vs conservative: MariTide risk overstated as near-term concern — commercial validation is 2027 story, not a Q3 binary event; using it as reason to refuse entry now overstates immediate risk

→ vs conservative: Macro argument inverted — stable macro means optionality reasonably priced, actually supports measured action not maximum patience; using stable macro as reason to be MORE cautious misreads the signal